GRI Bio, Inc. (NASDAQ:GRI) short interest fell 67.2% in September

GRI Bio, Inc. (NASDAQ:GRI – Get Free Report ) saw a significant drop in short interest in September. As of September 15th, there was short interest totaling 143,700 shares, a decrease of 67.2% from the August 31st total of 438,400 shares. Currently, 4.9% of the company’s shares are short sold. Based on an average daily volume of 653,200 shares, the short interest rate is currently 0.2 days.

GRI Bio Price Performance

NASDAQ GRI traded up 0.01 on Wednesday, reaching 0.47. 2,538,500 shares of the company traded hands, compared to its average volume of 278,613. The company’s 50-day moving average price is 0.66 and its 200-day moving average price is 3.71. GRI Bio has a 52 week low of 0.40 and a 52 week high of 161.98.

GRI Bio (NASDAQ:GRI – Get Your Free Report ) last posted its earnings results on Tuesday, August 13th. The company reported -4.92 earnings per share for the quarter.

Institutional investors intervene on GRI Bio

An institutional investor recently bought a new position in shares of GRI Bio. Armistice Capital LLC acquired a new stake in shares of GRI Bio, Inc. (NASDAQ:GRI – Free Report) during the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm purchased 50,207 shares of the company’s stock, valued at approximately $96,000. Armistice Capital LLC owned 9.23% of GRI Bio as of its most recent SEC filing. 33.95% of shares are owned by institutional investors and hedge funds.

GRI Bio company profile

(Get a free report)

GRI Bio, Inc, a clinical-stage biopharmaceutical company, focuses on treating inflammatory, fibrotic and autoimmune diseases in the United States. Its product line includes GRI-0621, which is in phase II clinical development for the treatment of idiopathic pulmonary fibrosis; GRI-0803 which is in phase I study for the treatment of systemic lupus erythematosus; GRI-0124, which is in preclinical development for the treatment of primary sclerosing cholangitis; and GRI-0729 in pre-clinical development.

Read more

Get news and reviews for GRI Bio Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for GRI Bio and related companies with MarketBeat.com’s FREE daily email newsletter.